Complement Factor I (C3b Inactivator)

A plasma serine proteinase that cleaves the alpha-chains of C3b and C4b in the presence of the cofactors COMPLEMENT FACTOR H and C4-binding protein, respectively. It is a 66-kDa glycoprotein that converts C3b to inactivated C3b (iC3b) followed by the release of two fragments, C3c (150-kDa) and C3dg (41-kDa). It was formerly called KAF, C3bINF, or enzyme 3b inactivator.

Also Known As:

C3b Inactivator; C3b-C4b Inactivator; C4b-C3b-INA; C4bC3bINA; Complement 3b-Complement 4b Inactivator; Complement C4b-C3b Inactivator; C3b C4b Inactivator; C4b C3b INA; C4b-C3b Inactivator, Complement; Complement 3b Complement 4b Inactivator; Complement C4b C3b Inactivator; Inactivator, C3b; Inactivator, C3b-C4b; Inactivator, Complement C4b-C3b

Networked: 109 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Kavanagh, David: 10 articles (06/2022 - 07/2005)
2.	Lotery, Andrew J: 5 articles (01/2022 - 01/2010)
3.	Blom, Anna M: 4 articles (01/2021 - 01/2008)
4.	Cree, Angela J: 4 articles (01/2021 - 01/2010)
5.	Java, Anuja: 3 articles (10/2022 - 01/2020)
6.	Kähäri, Veli-Matti: 3 articles (11/2021 - 02/2015)
7.	Nissinen, Liisa: 3 articles (11/2021 - 02/2015)
8.	Riihilä, Pilvi: 3 articles (11/2021 - 02/2015)
9.	Atkinson, John P: 3 articles (07/2015 - 01/2008)
10.	Fremeaux-Bacchi, Veronique: 3 articles (03/2011 - 01/2008)

Related Diseases

1.	Thrombotic Microangiopathies 07/30/2021 - "Genetic study revealed digenic mutation in Complement Factor I and C3 Therefore, it is important to differentiate aHUS from other thrombotic microangiopathies to improve the outcome." 10/01/2023 - "Role of the I416L Variant of Complement Factor I in Thrombotic Microangiopathy Among Patients of African Ancestry." 01/01/2023 - "IFNβ treatment may cause complement factor I deficit, which can lead to thrombotic microangiopathy and severe renal failure." 01/01/2022 - "Post-Transplant Thrombotic Microangiopathy due to a Pathogenic Mutation in Complement Factor I in a Patient With Membranous Nephropathy: Case Report and Review of Literature." 01/01/2020 - "Complement Factor I Mutation May Contribute to Development of Thrombotic Microangiopathy in Lupus Nephritis."
2.	Geographic Atrophy 01/01/2021 - "Prevalence and phenotype associations of complement factor I mutations in geographic atrophy." 07/01/2015 - "Association Between Growth of Geographic Atrophy and the Complement Factor I Locus." 07/01/2015 - "The association between the growth of geographic atrophy (GA) and a single nucleotide polymorphism (SNP) in the complement factor I (CFI) locus was investigated in the COMPLETE trial. " 06/01/2023 - "To evaluate associations between rare dysfunctional complement factor I (CFI) genetic variant status and progression to advanced age-related macular degeneration (AAMD), geographic atrophy (GA), and neovascular disease (NV). " 01/01/2017 - "A more substantial monthly treatment benefit of 44% reduction in geographic atrophy area progression versus sham control (95% CI, 15 to 73%) was observed in a subgroup of complement factor I (CFI) risk-allele carriers (57% of the patients analyzed were CFI risk-allele carriers). "
3.	Vasculitis (Vasculitides) 01/01/2022 - "In this study, frozen skin biopsies from the nonlesional skin, initial petechial lesion, and palpable purpura lesion from 10 patients with immunocomplex-mediated small vessel vasculitis were studied immunohistochemically for complement factor I, iC3b, CD11b, and CD14. "
4.	Purpura 01/01/2022 - "Already, the nonlesional skin revealed marked immunostaining of complement factor I, iC3b, CD11b, and CD14, and their expression increased sequentially in initial petechial and palpable purpura lesions. " 01/01/2022 - "In this study, frozen skin biopsies from the nonlesional skin, initial petechial lesion, and palpable purpura lesion from 10 patients with immunocomplex-mediated small vessel vasculitis were studied immunohistochemically for complement factor I, iC3b, CD11b, and CD14. "
5.	Glioma (Gliomas) 01/01/2020 - "The aim of our study was to evaluate the prognostic significance and function of the complement factor I (CFI) in glioma. " 01/01/2020 - "A Candidate Prognostic Biomarker Complement Factor I Promotes Malignant Progression in Glioma."

Related Drugs and Biologics

1.	chemotactic factor inactivator
2.	Complement C3b (C3bi)
3.	Complement System Proteins (Complement)
4.	Complement Factor B (Factor B)
5.	Complement Factor H (Factor H)
6.	Proteins (Proteins, Gene)
7.	Properdin
8.	Fibrinogen (Factor I)
9.	C3bINA
10.	Biomarkers (Surrogate Marker)

Related Therapies and Procedures

1.	Transplantation
2.	Plasma Exchange
3.	Nephrectomy